Cumulative iron dose and resistance to erythropoietin

Journal of Nephrology

Volumn 28, Issue 5, 2015, Pages 603-613

  Rosati, A ^a   Tetta, C ^b   Merello, J I ^c   Palomares, I ^c   Perez Garcia, R ^d   Maduell, F ^e   Canaud, B ^b   Aljama Garcia, P ^f  

^a Campo di Marte General Hospital   (Italy)

^b FRESENIUS MEDICAL CARE   (Germany)

^c AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^d HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; BIOLOGICAL MARKER; ERYTHROPOIETIN; IRON;

AGED; ANALYTICAL PARAMETERS; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DOSE CALCULATION; ERYTHROPOIETIN RESISTANCE INDEX; FEMALE; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; IRON THERAPY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICATION THERAPY MANAGEMENT; NEOPLASM; NUTRITIONAL PARAMETERS; PATIENT MONITORING; RETROSPECTIVE STUDY; RISK; TURBIDIMETRY; BLOOD; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; DRUG RESISTANCE; FOLLOW UP; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RENAL REPLACEMENT THERAPY;

AGED; ANEMIA; BIOMARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 84941193587     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-014-0127-3     Document Type: Article

References (42)

1. Elliott J, Mishler D, Agarwal R (2009) Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis 16(2):94–100
2. Yee J, Zasuwa G, Frinak S, Besarab A (2009) Hemoglobin variability and hyporesponsiveness: much ado about something or nothing? Adv Chronic Kidney Dis 16(2):83–93
3. Rambod M, Kovesdy CP, Kalantar-Zadeh K (2008) Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol 3:1691–1701
4. Lopez-Gomez JM, Portole´s JM, Aljama P (2008) Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int 74(Suppl 111):S75–S81
5. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR (2007) Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients’ response to IV iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol 18:975–984
6. Ford BA, Coyne DW, Eby CS, Scott MG (2009) Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney Int 75:104–110
7. Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP (2009) Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodyalisis patients. Am J Kidney Dis 53(5):823–834
8. Movilli E, Cancarini GC, Zani R et al (2001) Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in hemodialysis patients. Nephrol Dial Transplant 16:111–114
9. Locatelli F, Altieri P, Andrulli S, Sau G, Bolasco P, Pedrini LA, Basile C, David S, Feriani M, Nebiolo PE, Ferrara R, Casu D, Logias F, Tarchini R, Cadinu F, Passaghe M, fundoni G, Villa G, Di Iorio BR, Zoccali C (2012) Predictors of hemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux hemodyalisis, hemofiltration and hemodiafiltration: results of a multicentre randomized and controlled trial. Nephrol Dial Transpl 27:3594–3600
10. Hsu PY, Lin CL, Yu CC et al (2004) Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients —a prospective cross-over study. J Nephrol 17:693–700
11. Bossola M, Sanguinetti M, Scribano D, Zuppi C, Giungi S, Luciani G, Torelli R, Posteraro B, Fadda G, Tazza L (2009) Circulating bacterial-derived DNA fragments and markers of inflammation in chronic hemodialysis patients. Clin J Am Soc Nephrol 4:379–385
12. Roger S (2006) The CARI guidelines. Hematological targets. Iron Nephrol (Carlton) 11(Suppl 1):S217–S229
13. KDOQI (2006) Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47:S11–S145
14. Besarab A, Coyne DW (2010) Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 6(12):699–710
15. Charytan C, Qunibi W, Bailie GR (2005) Comparison of intravenous Fe sucrose to oral Fe in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 100:c55–c62
16. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S (2005) A randomized, controlled trial comparing IV Fe sucrose to oral Fe in anemic patients with nondialysis- dependent CKD. Kidney Int 68:2846–2856
17. Ganz T (2011) Hepcidin and iron regulation, 10 years later. Blood 117:4425–4433
18. Coyne DW (2011) Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int 80:240–244
19. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine E (1996) A randomized controlled study of Fe supplementation in patients treated with erythropoietin. Kidney Int 50:1694–1699
20. Taylor JE, Peat N, Porter C, Morgan AG (1996) Regular low dose intravenous Fe therapy improves response to erythropoietin in hemodialysis patients. Nephrol Dial Transplant 11:1079–1083
21. Feldman HI, Santana J, Guo W, Furst H, Franklin E, Joffe M, Marcus S, Faich G (2002) Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13:734–744
22. KDIGO Clinical Practice Guideline for Anemia in Chronic (2012) Kidney disease. Kidney Int Suppl 2:279–335
23. Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, Hörl W, London G, Vanholder R, Van Biesen W (2013) ERA-EDTA ERBP advisory board. Kidney disease: improving global outcomes guidelines on anemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transplant 28:1346–1359
24. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber BA, Mason NA, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM (2013) Variation in intravenous iron use internationally and over time: the dialysis outcomes and practice patterns study (DOPPS). Nephrol Dial Transplant 28(10):2570–2579
25. Zhang Y, Thamer M, Kshirsagar O, Cotter DJ (2013) Organizational status of dialysis facilities and patient outcome: does higher injectable medication use mediate increased mortality? Health Serv Res 48(3):949–971
26. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michel B, Warnock DG (2005) Time-dependent associations iron and mortality in hemodialysis patients. J Am Soc Nephrol 16:3070–3080
27. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH (2004) Association between serum ferritin and measures of inflammation, nutrition and Fe in hemodialysis patients. Nephrol Dial Transplant 19:141–149
28. Kalantar-Zadeh K, Lee GH (2006) The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol 1(Suppl 1):S9–S18
29. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R (2005) Noninvasive measurement and imaging of liver Fe concentrations using proton magnetic resonance. Blood 105:855–861
30. Ferrari P, Kulkarni H, Dheda S, Betti S, Harrison C, St. Pierre TG, OlynykJ JK (2011) Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 6:77–83
31. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, Roy M, Machado G, Janklewicz P, Drahi G, Dahan H, Cohen Y (2012) Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 125:991–999
32. Genzer H, Marschang P, Sturm W et al (2002) Association between increate iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol 40:2189–2194
33. Drüeke T, Witko-Sarsat V, Massy Z et al (2002) Iron therapy, advanced oxidation protein products and carotid artery intima-media thickness in end-stage renal disease. Circulation 106:2212–2217
34. Reis KA, Guz G, Ozdemir H et al (2005) Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J. 46:255–264
35. Van Buren P, Velez RL, Vaziri ND, Zhou XJ (2011) Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD. Int Urol Nephrol 44(2):499–507
36. Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen K, Krishnan M, Bradbury BD (2008) Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 3:1077–1083
37. Coyne DW (2010) It’s time to compare anemia management strategies in hemodialysis. Clin J Am Soc Nephrol 5(4):740–742
38. Papakonstantinou OG, Maris TG, Kostaridou V, Gouliamos AD, Koutoulas GK, Kalovidouris E, Papavassiliou GB, Kordas G, Kattamis C, Vlahos LJ, Papavassiliou CG (1995) Assessment of liver Fe overload by T2-quantitative magnetic resonance imaging: correlation of T2-QMRI measurements with serum ferritin concentration and histologic grading of siderosis. Magn Reson Imaging 13:967–977
39. Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, Thea A, Martina G, Piga A (2004) Validation of serum ferritin values by magnetic susceptometry in predicting Fe overload in dialysis patients. Kidney Int 65:1091–1098
40. Olynyk JK, Gan E, Tan T (2009) Predicting Fe overload in hyperferritinemia. Clin Gastroenterol Hepatol 7:359–362
41. Chiang CK, Yang SY, Peng YS, Hsu SP, Pai MF, Huang JW, Hung KY, Wu KD (2009) Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effects. Am J Nephrol 29(5):392–397
42. Sirken G, Kung SC, Raja R (2003) Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J 49(4):422–425